IL6 and lung carcinoma: However, PKCζ is not proinflammatory in all cases, for example, in a ras‐induced lung cancer model, PKCζ reduces IL‐6 expression by inhibiting the IL‐6 promoter's histone acetylation of the IL‐6 promoter (acting on the C/EBPβ element) to reduce IL‐6 expression, thereby exerting a tumor‐suppressive effect.